| Literature DB >> 34507616 |
Marie Camerota1,2, Stefan Graw3, Todd M Everson3,4, Elisabeth C McGowan5, Julie A Hofheimer6, T Michael O'Shea6, Brian S Carter7, Jennifer B Helderman8, Jennifer Check8, Charles R Neal9, Steven L Pastyrnak10, Lynne M Smith11, Lynne M Dansereau12, Sheri A DellaGrotta12, Carmen J Marsit3, Barry M Lester13,12,5.
Abstract
BACKGROUND: Prenatal risk factors are related to poor health and developmental outcomes for infants, potentially via epigenetic mechanisms. We tested associations between person-centered prenatal risk profiles, cumulative prenatal risk models, and epigenome-wide DNA methylation (DNAm) in very preterm neonates.Entities:
Keywords: Buccal; Epigenetics; Epigenome-wide association study (EWAS); Methylation; Neonatal; Prenatal; Preterm
Mesh:
Year: 2021 PMID: 34507616 PMCID: PMC8434712 DOI: 10.1186/s13148-021-01164-9
Source DB: PubMed Journal: Clin Epigenetics ISSN: 1868-7075 Impact factor: 6.551
Demographic and medical characteristics of the sample
| Sample characteristics | Full sample | Included | Excluded | |
|---|---|---|---|---|
| Maternal education: < HS/GED | 13% (79/598) | 15% (68/468) | 8.5% (11/130) | 0.07 |
| Low SES: Hollingshead = 5 | 9.9% (59/599) | 8.5% (40/469) | 15% (19/130) | 0.04 |
| Minority race or ethnicity± | 58% (347/601) | 55% (257/470) | 69% (90/131) | 0.004 |
| No partner | 25% (152/600) | 26% (124/470) | 22% (28/130) | 0.26 |
Means ± standard deviations (continuous) or percentage and frequencies (categorical) of demographic and medical characteristics. p-values refer to the comparison of included versus excluded individuals and were obtained from t-tests (continuous variables) and chi-squared tests (categorical variables)
PMA, postmenstrual age; HS, high school; GED, General Equivalency Diploma; SES, socioeconomic status
*All mothers with prenatal data were included in the latent class analysis. Included versus excluded in this Table refers to individuals with data for the epigenome-wide analysis
±Minority race or ethnicity was defined as any non-White race (e.g., Black, Asian) or ethnicity (e.g., Hispanic and/or Latino/a)
+Serious brain injury included parenchymal echodensity, periventricular leukomalacia, or ventricular dilation diagnosed via cranial ultrasound
Distribution of individual prenatal risk factors in full sample and by latent class
| Prenatal risk factors | Full sample | Typical | Physical risk | Psychological risk | |
|---|---|---|---|---|---|
| Age > 35 | 18% | 18% | 18% | 14% | 0.89 |
| Low SES | 10% | 6.5% | 14% | 18% | 12.78** |
| < HS degree | 13% | 12% | 9.8% | 26% | 12.54** |
| Minority | 58% | 57% | 56% | 66% | 2.45 |
| No partner | 25% | 21% | 18% | 62% | 65.33*** |
| No prenatal care | 2.7% | 1.6% | 1.9% | 9.1% | 14.01*** |
| Underweight | 5.0% | 5.8% | 0.0% | 12% | 15.48*** |
| Obese | 34% | 26% | 53% | 33% | 35.11*** |
| Too much weight gained | 18% | 12% | 34% | 17% | 33.93*** |
| Hypertension | 27% | 3.3% | 95% | 3.9% | 490.33*** |
| Pre-eclampsia | 21% | 0.0% | 79% | 0.0% | 442.57*** |
| Diabetes | 6.0% | 5.5% | 9.7% | 1.3% | 7.00* |
| STI/HIV | 7.0% | 5.0% | 6.5% | 18% | 16.33*** |
| Infection | 10% | 10% | 9.0% | 14% | 1.39 |
| Alcohol | 3.2% | 1.4% | 2.6% | 13% | 27.18*** |
| Illegal substances | 4.5% | 0.3% | 4.5% | 24% | 85.30*** |
| Tobacco | 14% | 8.0% | 14% | 44% | 70.36*** |
| Marijuana | 10% | 4.1% | 8.4% | 41% | 96.07*** |
| Depression | 11% | 4.9% | 10% | 39% | 79.51*** |
| Anxiety | 12% | 7.4% | 9.7% | 35% | 50.62*** |
| Pregnancy “Hard Time” | 11% | 6.7% | 6.5% | 42% | 86.18*** |
| Pregnancy “Felt Down” | 9.9% | 2.7% | 5.9% | 51% | 173.87*** |
| Pregnancy “Felt Slow” | 20% | 13% | 23% | 46% | 44.90*** |
| Pregnancy “Felt Hopeless” | 3.9% | 0.3% | 1.3% | 26% | 115.30*** |
STI, sexually transmitted infection; HIV, Human immunodeficiency virus
*p < .05, **p < .01, ***p < .001
Fig. 1Rates of endorsement of 24 prenatal risk factors by latent class membership. Women in class 1 (green; 61%) endorse few prenatal risk factors. Women in class 2 (red; 26%) endorse elevated physical health problems, whereas women in class 3 (blue; 13%) endorse elevated substance use and psychological problems
Epigenome-wide association study results for CpG sites that yielded significant associations after Bonferroni adjustment
| CpG | Location | Gene annotation | Coefficient (m-value) | Coefficienta (beta-value) | Brain-buccal correlation | ||
|---|---|---|---|---|---|---|---|
| cg25123362 | Chr10: 133793734 | − 0.25 | 2.76E−11 | 1.95E−05 | − 0.05 | − 0.09 | |
| cg08930413 | Chr7: 151548036 | − 0.28 | 2.11E−08 | 1.49E−02 | − 0.04 | 0.22 | |
| cg16999677 | Chr5: 843982 | − 2.05 | 6.85E−08 | 4.84E−02 | − 0.05 | 0.61** | |
| cg05324191 | Chr1: 116994757 | LOC101929023 (Body) | 1.03 | 1.30E−09 | 9.18E−04 | 0.02 | − 0.33 |
| cg01533736 | Chr20: 22542854 | − 1.18 | 1.17E−09 | 8.25E−04 | − 0.03 | 0.40 | |
| cg00569188 | Chr21: 41122530 | − 1.28 | 4.61E−08 | 3.26E−02 | − 0.03 | − 0.17 | |
| cg09979763 | Chr1: 245499904 | − 2.02 | 4.23E−08 | 2.99E−02 | − 0.03 | − 0.07 | |
| cg11420269 | Chr16: 70516713 | − 1.46 | 2.07E−08 | 1.46E−02 | − 0.03 | 0.02 | |
| cg27514986 | Chr15: 39486981 | 2.78 | 9.74E−09 | 6.88E−03 | 0.05 | 0.19 | |
| cg05636131 | Chr7: 148844053 | − 1.09 | 6.93E−08 | 4.90E−02 | − 0.02 | 0.42‡ | |
| cg11531492 | Chr3: 125673505 | − 2.63 | 6.56E−08 | 4.63E−02 | − 0.05 | − 0.08 | |
| cg26760502 | Chr14: 105493800 | − 0.88 | 4.89E−08 | 3.45E−02 | − 0.01 | − 0.09 | |
| cg19573457 | Chr22: 25893657 | − 1.68 | 2.17E−08 | 1.53E−02 | − 0.04 | 0.44* | |
| cg01284858 | Chr10: 123902371 | 3.61 | 6.20E−09 | 4.38E−03 | 0.06 | − 0.32 | |
| cg12155575 | Chr3: 186965150 | − 1.16 | 8.97E−09 | 6.33E−03 | − 0.03 | 0.08 | |
| cg11221492 | Chr14: 36790270 | − 0.90 | 3.92E−08 | 2.77E−02 | − 0.01 | 0.54* | |
| cg22102865 | Chr7: 148844067 | − 1.24 | 1.37E−08 | 9.64E−03 | − 0.02 | 0.46* |
aNote that the coefficient for cumulative risk models represents the expected increase in % DNAm associated with a 10% increase in risk. ‡p < .10, *p < .05, **p < .01, + indicates closest gene. Adjusted p-value is Bonferroni corrected
Fig. 2Manhattan plot of epigenetic loci associated with cumulative prenatal risk. The x-axis shows the genomic location of individual CpG sites and the y-axis shows the −log10(p values) from models relating cumulative prenatal risk to CpG methylation, adjusting for child sex, recruitment site, postmenstrual age at collection, sample batch, and cellular heterogeneity. Gene annotations have been added for all CpGs yielding significant associations after Bonferroni adjustment. The horizontal red line depicts the Bonferroni adjusted p-value threshold (α = 0.05/706323). +indicates closest gene
CpGs associated with prenatal risk are linked to genes that have been associated with traits in the GWASdb
| Gene | Traits (N) | Selected traits |
|---|---|---|
| 8 | Self-reported educational attainment, intelligence, mathematical ability, household income, schizophrenia, cognitive function | |
| 38 | Self-reported educational attainment, mathematical ability, brain/neuroimaging measurement, gut microbiome measurement, white matter microstructure, cardiovascular disease, brain volume measurement, bipolar disorder, psychotic symptoms, cognitive function | |
| 1 | Myopia age of onset | |
| – | – | |
| 4 | Body mass index, fasting blood glucose measurement, birth weight | |
| 4 | Systolic blood pressure, hypertension, short-term memory, health literacy | |
| 15 | Brain volume/neuroimaging measurement, response to SSRI, unipolar depression, diet measurement, brain measurement, schizophrenia | |
| 3 | Body height, body weight, body mass index | |
| 1 | Dihydroxy docosatrienoic acid measurement | |
| 10 | Brain volume/neuroimaging measurement, white blood cell count | |
| – | – | |
| 1 | Telomere length | |
| 4 | Bipolar disorder | |
| 16 | Opioid dependence, metabolite measurement, body weight gain, schizophrenia, body height, reaction time measurement | |
| 3 | Type 2 diabetes | |
| 6 | Self-reported educational attainment, hypertension |